Toxicity and anti-diabetic effectiveness of polymeric nanoparticles containing natural compounds
Abstract
Objective: To develop the nanoparticle formulations, characterization and evaluation of safety and in vivo anti diabetic potential by using experimental animal model.
Methods: Different nano formulations such as Cur-nanoparticles, Pip-nanoparticles as well as Cur-Pip dual drug loaded nanoparticles were developed by nano co-precipitation method. The developed formulations were subjected for FT-IR analysis to determine the drug-drug and drug-polymer interaction. The Differential Scanning Colorimetric (DSC) study was carried out to observe the glass transition. Surface topography of nano formulations were carried out by Scanning Electron Microscopy (SEM). X-ray diffraction study was carried out to determine the crystalline properties of different formulations. Particle size of the polymeric nanoparticles was evaluated by Zeta sizer of nanoseries. Toxicity of nanoformulation was evaluated as per OECD guideline-407. For evaluation of therapeutic effectiveness, in-vivo anti-diabetic potential of nano formulations, the Streptozotocin (STZ) induced diabetes model was considered.
Results: The developed formulations were spherical in shape and smooth surfaced. There were no interaction between the drugs and polymers. The result of toxicity study revealed that, there were no changes in behavior, food intake; hematology as well as biochemical parameters were observed that indicates the developed formulation is completely safe. The anti-diabetic effect of different formulations was screened against Streptozotocin induced diabetes in experimental animals. All the formulations were proved as effective in restoring blood glucose level however, Cu+Pi NP (184.15) group showed highest anti diabetic activity in comparison to control group (207.93)
Conclusions: From this study, it was observed that, Curcumin-Piperine dual drug loaded nanoparticles exhibit better anti diabetic potential in comparison to control and Curcumin-NP treated group.
Keywords: Nanoparticles, Streptozotocin, anti-diabetes, toxicity, hematology, biochemical
Keywords:
Nanoparticles, Streptozotocin, anti-diabetes, toxicity, hematology, biochemicalDOI
https://doi.org/10.22270/jddt.v13i12.6089References
Hameed I, Masoodi SR, Mir SA, Nabi M, Ghazanfar K, Ganai BA. Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition. World J Diabetes 2015; 6(4): 598-612. https://doi.org/10.4239/wjd.v6.i4.598 PMid:25987957 PMCid:PMC4434080
Satapathy T, Mishra G, Panda PK. Animal models for Type-2 diabetes: A review. World Journal of Pharmaceutical Sciences.2016; 4(1):141-147.
Dandona L. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990-2016. Lancet Public Health. 2018; 3: 478-89. https://doi.org/10.1016/S2468-2667(18)30138-5 PMid:30219340
Andersen DK , Sandberg AA, Duell EJ, Goggin M , Korc M , Petersen GM et.al. Whitcomb, Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI Workshop, Pancreas.(2013); 42 (8):1227-1237. https://doi.org/10.1097/MPA.0b013e3182a9ad9d PMid:24152948 PMCid:PMC3878448
Sinha D, Satapathy T, Dewangan MK, Kumar A, Roy A. Recent status on carbohydrate metabolizing enzyme inhibitors in regulation of diabetes: a mechanism based review. Journal of applied Pharmaceutical Research. 2015;3(2):1-7.
Matveyenko AV, Dry S, Cox Moshtaghian Gurlo TA, Galasso R et.al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin, Diabetes. (2009); 58 (7):1604-1615. https://doi.org/10.2337/db09-0058 PMid:19403868 PMCid:PMC2699878
Manach C, Scalbert A, Morand C. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004;79:727-747. https://doi.org/10.1093/ajcn/79.5.727 PMid:15113710
Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med. 1991; 57:1-7. https://doi.org/10.1055/s-2006-960004 PMid:2062949
Rajasekaran SA. Therapeutic potential of Curcumin in gastrointestinal diseases. World J Gastrointest Pathophysiol 2011; 2(1):1-14. https://doi.org/10.4291/wjgp.v2.i1.1 PMid:21607160 PMCid:PMC3097964
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of Curcumin: problems and promises. Mol Pharm 2007; 4(6):807-818. https://doi.org/10.1021/mp700113r PMid:17999464
Aggarwal BB, Harikumar KB. Potential therapeutic effects of Curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009; 41:40. https://doi.org/10.1016/j.biocel.2008.06.010 PMid:18662800 PMCid:PMC2637808
Kesarwani K, Gupta R. Bioavailability enhancers of herbal origin: An overview. Asian Pacific Journal of Tropical Biomedicine, 2013; 3(4):253-266. https://doi.org/10.1016/S2221-1691(13)60060-X PMid:23620848
Mosallanezhad P, Nazockdast H, Ahmadi Z, Rostami A. Fabrication and characterization of Polycaprolactone/Chitosan nanofibers containing antibacterial agents of Curcumin and ZnO nanoparticles for use as wound dressing. Bioeng.Biotechnol.2022; 10:1-14. https://doi.org/10.3389/fbioe.2022.1027351 PMid:36213068 PMCid:PMC9539460
Satapathy T, Panda PK, Goyal AK, Rath G. Evaluation of anti-GERD activity of gastro retentive drug delivery system of itopride hydrochloride. Artificial Cells, Blood Substitutes, and Biotechnology. 2010; 38 (4):200-207. https://doi.org/10.3109/10731191003776751 PMid:20515421
Satapathy T and Panda PK. Solid Lipid Nanoparticles: A Novel Carrier in Drug Delivery System.2013; 5(2):56-61.
Elavarasan A. EDX and XRD, FT-IR spectra, analysis containing hexavalent chromium metal ion adsorption present in aqueous solution on to phosphoric acid (h 3 po 4) activated Mimusops elengi leaves carbon. Journal of Drug Delivery & Therapeutics. 2018; 8(5-s):132-138. https://doi.org/10.22270/jddt.v8i5-s.1917
Togbossi LA, Lawson-Evi P, Atchou NK, Motto EA et.al. In vivo assessment of acute and sub chronic toxicity of hydro ethanolic extract of Ximenia americana L. (Olacaceae) stem bark. Journal of Drug Delivery & Therapeutics. 2022; 12(4):81-86. https://doi.org/10.22270/jddt.v12i4.5567
Published
Abstract Display: 453 
PDF Downloads: 388 PDF Downloads: 154 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.